摘要
目的:研究本院现有的5个品种三七总皂苷注射剂应用于急性脑梗死治疗的经济效果。方法:检索2000-2007年在生物医学期刊上发表的该5个品种三七总皂苷和复方丹参注射液对照治疗脑梗死的临床研究文献,将符合标准的试验纳入本次研究,再以其现在的价格等数据作成本-效果分析。结果:5个品种成本分别为:A组(血栓通注射液)330.96元、B组(血塞通注射液)707.84元、C组(路路通注射液)1737.68元、D组(注射用血栓通)2015.44元、E组(注射用血塞通)1074.08元;有效率分别为85.5%、96.7%、92.3%、93.3%、96.0%;成本-效果比分别为A组3.87、B组7.32、C组18.83、D组21.60、E组11.18;以方案A为参照的增量成本-效果分别是:B组103.54、C组114.70、D组94.00、E组99.08。结论:B组方为最佳方案。
OBJECTIVE: To study the cost - effectiveness of five kinds of Saponins of Panax Notoginseng Injection for patients with acute cerebral infarction in our hospital. METHODS: Clinical controlled trials that compare Saponins of Panax Notoginseng with the Compound Danshen injection in the treatment of acute cerebral infarction were retrieved from biomedical science periodical (from 2000 to 2007)and the clinical trials meeting the inclusion criteria were included in our study. A cost - effectiveness analysis was performed based on the data such as the present price etc. RESULTS: The costs of Group A (Xueshuantong injection), B (Xuesaitong injection), C (Lulutong injection), D (Xueshuangtong for injection), and E (Xuesaitong for injection)were 330.96, 707.84, 1737.68, 2015.44, and 1074.08 yuan respectively; The effective rates were 85.5 %, 96.7 %, 92.3 %, 93.3 %, and 96.0% respectively; The cost - effectiveness ratios were 3.87, 7.32, 18.83, 21.60, and 11.18, respectively, and the increments of cost-effectiveness of Group B, C, D, and E were 103.54, 114.70, 94.00, and 99.08 as against Group A. CONCLUSION: Scheme B is preferable choice among the 5 schemes
出处
《中国医院用药评价与分析》
2008年第7期524-524,525,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
三七总皂苷
复方丹参注射液
脑梗死
成本-效果分析
Saponins of panax notoginseng
Compound danshen injection
Acute cerebral infarction
Cost - effectiveness analysis